01 September, 2017
The Kingdon Capital Management Llc holds 145,474 shares with $5.06M value, down from 272,526 last quarter. Teachers Advisors LLC increased its stake in La Jolla Pharmaceutical by 12.4% in the fourth quarter. The stock decreased 0.44% or $0.15 during the last trading session, reaching $34.16.
La Jolla Pharmaceutical Company (LJPC) opened at 29.72 on Friday. It has outperformed by 111.95% the S&P500. Bank of New York Mellon Corp increased its stake in La Jolla Pharmaceutical by 6.5% in the first quarter. Almost 0.68 million shares were traded by the close, higher than its average daily volume of 0.27 million shares. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has risen 3.00% since August 30, 2016 and is uptrending. It has underperformed by 6.19% the S&P500. (POWL) has declined 1.56% since August 30, 2016 and is downtrending. Its up 0.05, from 1.01 in 2016Q3. 0 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data. Northern Tru Corporation accumulated 197,420 shares. Janus Cap Mngmt invested in 0.02% or 1.14 million shares. Tocqueville Asset Mngmt LP holds 0.01% or 50,000 shares in its portfolio. Fmr Ltd Liability Company reported 2.74 million shares. Carderock Cap Mngmt holds 27,921 shares or 1.79% of its portfolio. 17,525 were reported by National Planning Corp. Advsrs Asset Mgmt Inc accumulated 40,237 shares. Legal & General Group Plc now owns 4,456 shares of the biopharmaceutical company's stock worth $133,000 after buying an additional 462 shares during the period. Bokf Na reported 0.03% stake. On Monday, August 22 the stock rating was upgraded by Deutsche Bank to "Buy".
Kingdon Capital Management Llc decreased Amag Pharmaceuticals Inc (AMAG) stake by 46.62% reported in 2016Q4 SEC filing.
Several large investors have recently bought and sold shares of LJPC. Teligent Inc New was reduced too. The stock is a Buy among 3 brokerage firms polled by Factset Research. Therefore 20% are positive. La Jolla Pharmaceutical had 2 analyst reports since May 1, 2017 according to SRatingsIntel. The rating was maintained by Chardan Capital Markets on Tuesday, September 8 with "Buy". Morgan Stanley upgraded Bancolombia SA (ADR) (NYSE:CIB) on Tuesday, December 13 to "Overweight" rating. The firm has "Sell" rating given on Wednesday, March 16 by UBS. The rating was maintained by Jefferies with "Buy" on Monday, June 12. The stock has "Neutral" rating by JP Morgan on Wednesday, October 28.
Since March 2, 2017, it had 1 insider buy, and 0 insider sales for $5.00 million activity.
La Jolla Pharmaceutical (NASDAQ:LJPC) last released its earnings results on Thursday, July 27th. The insider MULROY DENNIS bought 500 shares worth $16,975. $102,505 worth of La Jolla Pharmaceutical Company (NASDAQ:LJPC) was bought by TIDMARSH GEORGE F. $34,460 worth of La Jolla Pharmaceutical Company (NASDAQ:LJPC) shares were bought by CARVER JENNIFER. Chawla Lakhmir S bought $55,678 worth of stock or 1,600 shares.
Investors sentiment decreased to 1.81 in Q4 2016. Its down 1.05, from 2.86 in 2016Q3. It worsened, as 14 investors sold LJPC shares while 16 reduced holdings. 5 funds opened positions while 22 raised stakes. 2,654 were accumulated by Great West Life Assurance Can. 21,579 are owned by Schwab Charles Mgmt. Van Den Berg Management I Inc owns 132,157 shares or 0.61% of their United States portfolio. Alliancebernstein Ltd Partnership reported 12,700 shares or 0% of all its holdings. Legal And General Public Ltd Co holds 3,994 shares. At present, 0 analysts call it Sell, while 0 think it is Hold. Royal Comml Bank Of Canada reported 0% in La Jolla Pharmaceutical Company (NASDAQ:LJPC). The New York-based Pointstate Capital L P has invested 0.05% in La Jolla Pharmaceutical Company (NASDAQ:LJPC).
La Jolla Pharmaceutical Company has a consensus outperform rating from 5 Wall Street analysts, and the number of shares now sold short amount to at least 21.27% of shares outstanding. Bnp Paribas Arbitrage owns 779 shares. Moreover, Metropolitan Life Insurance has 0% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Therefore 100% are positive. Wall Street is only getting more bullish on the stock, with 5 of analysts who cover LJPC having a buy-equivalent rating. $48.33's average target is 40.86% above currents $34.31 stock price. The firm earned "Buy" rating on Wednesday, December 16 by HSBC. The rating was maintained by Jefferies on Monday, July 24 with "Buy". On Tuesday, August 11 the stock rating was downgraded by Zacks to "Hold". The firm has "Buy" rating given on Tuesday, May 23 by SunTrust.
